Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Neeraj Sinha

Pulmonary Disease Miami, FL Medical Doctor

NPI 1891745543 CMS profile 358752

1801 Nw 9Th Ave, Miami, FL 33136

Open in the dashboard

General payments

$3,762

50 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$18,812 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Neeraj Sinha of Miami, FL is reported in the CMS Open Payments database as having received $3,762 across 50 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $18,812 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 62nd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $414 8
2024 General $955 16
2023 General $830 10
2022 General $196 2
2021 General $267 4
2020 General $854 8
2019 General $245 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neeraj Sinha
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Neeraj Sinha were reported at $414. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Neeraj Sinha Pulmonary Disease median Middle half National median
2019 $245 $377 $109–$1,340 $163
2020 $854 $230 $56–$907 $114
2021 $267 $269 $68–$1,072 $132
2022 $196 $390 $100–$1,457 $149
2023 $830 $419 $114–$1,659 $160
2024 $955 $476 $123–$1,818 $164
2025 $414 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $1,898 21 payments
  2. Fisher & Paykel Healthcare Inc $489 3 payments
  3. Outset Medical Inc $242 1 payment
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $186 6 payments
  5. Medtronic Vascular, Inc. $131 1 payment
  6. Mallinckrodt Hospital Products Inc. $114 1 payment
  7. Abbott Laboratories $113 1 payment
  8. United Therapeutics Corporation $105 1 payment
  9. One Lambda, Inc. $101 1 payment
  10. Ambu Inc. $95 4 payments
  11. Other $288 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,284 37 payments
  2. Consulting Fee $788 4 payments
  3. Education $690 9 payments
Products named General payments · program years 2019–2025
  1. CRESEMBA Hospital And Transplant $788 4 payments
  2. FISHER & PAYKEL HEALTHCARE Nasal High Flow $489 3 payments
  3. FISHER & PAYKEL HEALTHCARE Nasal High Flow $489 3 payments
  4. FISHER & PAYKEL HEALTHCARE Nasal High Flow $489 3 payments
  5. FISHER & PAYKEL HEALTHCARE Nasal High Flow $489 3 payments
  6. FISHER & PAYKEL HEALTHCARE Nasal High Flow $489 3 payments
  7. Cresemba Infectious Diseases $414 7 payments
  8. HeartWare HVAD $131 1 payment
  9. ACTHAR $114 1 payment
  10. Trifecta GT Tissue Heart Valve $113 1 payment
  11. Other $430 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

255

Median for Pulmonary Disease: 936

Drug cost

$10,683

Median for Pulmonary Disease: $487,987

Branded share of claims

15.3%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mycophenolate Mofetil Generic 21 $3,850
Tacrolimus Generic 20 $3,733
Azithromycin Generic 60 $1,219
Ibandronate Sodium Generic 16 $569
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 39 $377
Pantoprazole Sodium Generic 23 $346
Rosuvastatin Calcium Generic 32 $254
Azelastine Hcl Generic 11 $148
Prednisone Generic 21 $142
Levothyroxine Sodium Generic 12 $45

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$19,786

Medicare's payments for the services billed

Medicare patients

83

Average age 72

Services billed

229

39 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 60%
Ischemic heart disease 48%
Arthritis 46%
Chronic kidney disease 41%
Heart failure 37%
Diabetes 35%
Atrial fibrillation 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Cresemba
  • Astellas Pharma US Inc $154
$154 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $89
$89 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $77
$77 — —
LIVTENCITY
  • Takeda Pharmaceuticals U.S.A., Inc. $35
$35 — —
DUPIXENT
  • SANOFI PASTEUR INC. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

50 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record